Bray Capital Advisors raised its holdings in Johnson & Johnson (NYSE:JNJ) by 2.2% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 24,554 shares of the company’s stock after acquiring an additional 518 shares during the period. Johnson & Johnson comprises about 1.3% of Bray Capital Advisors’ investment portfolio, making the stock its 20th largest holding. Bray Capital Advisors’ holdings in Johnson & Johnson were worth $3,453,000 at the end of the most recent quarter.
Several other institutional investors have also made changes to their positions in JNJ. Hemenway Trust Co LLC lifted its stake in Johnson & Johnson by 0.9% in the second quarter. Hemenway Trust Co LLC now owns 148,892 shares of the company’s stock valued at $20,939,000 after buying an additional 1,359 shares in the last quarter. Coho Partners Ltd. raised its holdings in shares of Johnson & Johnson by 2.3% during the second quarter. Coho Partners Ltd. now owns 1,334,586 shares of the company’s stock worth $187,683,000 after acquiring an additional 30,473 shares during the period. Vident Investment Advisory LLC lifted its position in Johnson & Johnson by 25.1% in the 2nd quarter. Vident Investment Advisory LLC now owns 40,948 shares of the company’s stock valued at $5,759,000 after acquiring an additional 8,228 shares in the last quarter. Douglas Lane & Associates LLC boosted its stake in Johnson & Johnson by 18.4% in the 2nd quarter. Douglas Lane & Associates LLC now owns 147,220 shares of the company’s stock worth $20,704,000 after purchasing an additional 22,898 shares during the period. Finally, Cypress Asset Management Inc. TX increased its holdings in Johnson & Johnson by 4.9% during the 2nd quarter. Cypress Asset Management Inc. TX now owns 41,441 shares of the company’s stock worth $5,828,000 after purchasing an additional 1,939 shares in the last quarter. Institutional investors own 68.44% of the company’s stock.
Shares of JNJ stock opened at $145.76 on Friday. Johnson & Johnson has a 52-week low of $109.16 and a 52-week high of $157.00. The stock has a market cap of $383.76 billion, a price-to-earnings ratio of 21.31, a PEG ratio of 3.23 and a beta of 0.69. The firm’s 50-day moving average is $144.04 and its 200-day moving average is $144.14. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.05 and a current ratio of 1.25.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Thursday, July 16th. The company reported $1.67 earnings per share for the quarter, topping analysts’ consensus estimates of $1.50 by $0.17. Johnson & Johnson had a return on equity of 35.21% and a net margin of 22.69%. The firm had revenue of $18.34 billion for the quarter, compared to the consensus estimate of $17.73 billion. During the same quarter in the previous year, the business earned $2.58 earnings per share. The business’s revenue was down 10.8% compared to the same quarter last year. Sell-side analysts predict that Johnson & Johnson will post 7.85 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th will be issued a dividend of $1.01 per share. This represents a $4.04 annualized dividend and a yield of 2.77%. The ex-dividend date of this dividend is Monday, August 24th. Johnson & Johnson’s dividend payout ratio is 46.54%.
Several research analysts have recently weighed in on JNJ shares. Zacks Investment Research cut Johnson & Johnson from a “hold” rating to a “sell” rating and set a $150.00 price objective for the company. in a research report on Tuesday, July 7th. Credit Suisse Group reaffirmed a “buy” rating and set a $161.00 price target on shares of Johnson & Johnson in a research report on Tuesday, April 28th. Raymond James lifted their price objective on shares of Johnson & Johnson from $157.00 to $158.00 and gave the company an “outperform” rating in a report on Friday, July 17th. Citigroup boosted their price objective on shares of Johnson & Johnson from $165.00 to $170.00 and gave the stock a “buy” rating in a research report on Friday, July 17th. Finally, UBS Group downgraded shares of Johnson & Johnson from a “buy” rating to a “neutral” rating and decreased their target price for the company from $163.00 to $160.00 in a research report on Tuesday, April 28th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and twelve have assigned a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $163.38.
In other Johnson & Johnson news, EVP Ashley Mcevoy sold 29,000 shares of Johnson & Johnson stock in a transaction on Tuesday, July 28th. The shares were sold at an average price of $147.47, for a total transaction of $4,276,630.00. Following the completion of the transaction, the executive vice president now directly owns 21,682 shares of the company’s stock, valued at $3,197,444.54. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 0.27% of the company’s stock.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Featured Article: What does a bar chart display?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.